<DOC>
	<DOCNO>NCT02090725</DOCNO>
	<brief_summary>The main purpose study provide access 3,4 DAP , drug demonstrate effective treating weakness associate Lambert-Eaton Myasthenic Syndrome . LEMS rare autoimmune cause defect neuromuscular transmission . The disorder clinically characterize fluctuating muscle weakness , hyporeflexia autonomic dysfunction .</brief_summary>
	<brief_title>Controlled Trial 3,4-Diaminopyridine ( 3-4DAP ) Lambert-Eaton Myasthenic Syndrome ( LEMS )</brief_title>
	<detailed_description>More half LEMS case associate malignancy , usually small cell lung cancer . These paraneoplastic case progress quickly primary autoimmune LEMS . An overlap syndrome autoimmune disease often detect LEMS patient . 3,4 DAP effective LEMS increase calcium influx nerve terminal blocking potassium efflux thereby prolong presynaptic action potential . 3,4 DAP less likely provoke epileptic seizure precursor , 4-aminopyridine , less able cross blood-brain barrier . 3,4 DAP effective increase strength improve autonomic symptom LEMS patient primary autoimmune paraneoplastic etiology .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Male female majority 45 60 year age diagnose LambertEaton Myasthenic Syndrome . subject must take full dose pyridostigmine subject history liver problem ? subject history prolong QTc syndrome ( condition prolongation start Q wave end T wave heart 's electrical cycle ) .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>fluctuate muscle weakness</keyword>
	<keyword>hyporeflexia</keyword>
	<keyword>autonomic Dysfunction</keyword>
</DOC>